Advanced Search:
Equity Index Forex Crypto Commodity

RDUS - Radius Health

$17.42  -0.57 (-3.17%)

Updated: 16:43 Apr 30, 2024 EST

Next Hour's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Session's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Week's AI Forecast

N/A

Trend's Accuracy (AI)

N/A

Radius Health's Position Within the Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

RADIUS HEALTH - HISTORICAL DATA 6M

  • Last price

    $ 17.42

  • Daily change

    $ -0.57

  • Previous Close

    $ 17.99

  • Last Updated

    16:43 Apr 30, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 -0.98 -0.65 -0.27 -0.18

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 2.76 2.97 2.39 2.09

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
N/A 100% 45.91% 8.95%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
0 -100% 17.96 -5.27% 18.96 -20.2% 23.76

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
1.41 64.54 0.47 58.51

Radius Health Technical Analysis News

Radius Health

22 Boston Wharf Road
7th Floor
Boston, MA 02210
United States
617 551 4000
https://radiuspharm.com

Description

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

Corporate Governance

Radius Health, Inc.’s ISS Governance QualityScore as of July 1, 2022 is 6. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 4; Compensation: 6.

RADIUS HEALTH'S HOLDERS RANK

List of holders with stock participation in Radius Health.

Holder Rank Holder Shares Date Reported % Out Value